Table 2.
Baseline patient demographics and characteristics for the T2D groups, post PSM.
| Tirzepatide group (n = 4223) | Semaglutide group (n = 4223) | SSMD | |
|---|---|---|---|
| Demographics | |||
| Age at index event (years) | 53.9 ± 10.7 | 54.0 ± 12.2 | 0.012 |
| Sex (Female) [%] | 60 | 60 | 0.002 |
| Race (White/Black/Asian) [%] | 68/15/3 | 69/14/3 | 0.027/0.005/0.010 |
| Biochemistry and anthropometrics | |||
| Weight (kg) | 107.1 ± 26.6 | 105.1 ± 25.9 | 0.080 |
| Estimated glomerular filtration rate (ml/min/1.73 m2) | 83.8 ± 23.4 | 82.9 ± 26.0 | 0.035 |
| Triglycerides (mmol/mol) | 1.9 ± 1.4 | 2.0 ± 1.4 | 0.071 |
| Total cholesterol (mmol/mol) | 4.2 ± 1.1 | 4.2 ± 1.1 | 0.055 |
| Systolic blood pressure (mmHg) | 128.5 ± 16.4 | 128.9 ± 16.1 | 0.027 |
| HbA1c [%] | |||
| ≥6.5%, ≤7.5% | 40.9 | 39.8 | 0.007 |
| >7.5%, ≤8.5% | 27.9 | 27.5 | 0.001 |
| >8.5%, ≤9.5% | 15.9 | 17.1 | 0.031 |
| >9.5% | 15.3 | 15.6 | 0.010 |
| Co-morbidities [%] | |||
| Ischaemic heart diseases | 10.5 | 10.8 | 0.008 |
| Cerebrovascular diseases | 2.4 | 2.2 | 0.011 |
| Hypertensive diseases | 71.0 | 71.3 | 0.005 |
| Heart failure | 5.2 | 5.5 | 0.013 |
| Atrial fibrillation & flutter | 4.1 | 4.1 | 0.002 |
| Chronic kidney disease | 9.3 | 9.4 | 0.001 |
| Neoplasms | 18.0 | 18.1 | 0.004 |
| Chronic lower respiratory diseases | 14.6 | 14.4 | 0.005 |
| Drug treatment [%] | |||
| Oral hypoglycaemic agents | 63.9 | 64.6 | 0.015 |
| Insulin | 35.4 | 35.8 | 0.010 |
| Lipid lowering agents | 56.0 | 56.0 | 0.001 |
| ACE inhibitors | 23.7 | 24.4 | 0.016 |
| Diuretics | 30.9 | 30.5 | 0.007 |
| Beta blockers | 23.7 | 23.1 | 0.015 |
| Angiotensin II inhibitors | 25.2 | 24.7 | 0.011 |
| Antiarrhythmics | 26.0 | 25.2 | 0.018 |
| Platelet aggregation inhibitors | 10.4 | 10.7 | 0.009 |
| Anticoagulants | 10.5 | 9.8 | 0.025 |
| Lifestyle factors [%] | |||
| Tobacco use | 2.0 | 2.2 | 0.016 |
| Persons with potential health hazards related to socioeconomic and psychosocial circumstances | 1.8 | 1.5 | 0.019 |
SSMD: strictly standardised mean difference.